Biogen Stock Target Price and Analyst Consensus

BIIB Stock  USD 230.06  6.74  2.85%   
The prevalent analyst and expert consensus on Biogen is Strong Buy with 16 strong buy estimates. The prevailing projected target price is 330.76 with 35 professional opinions. Biogen buy-or-sell recommendation and consensus module provides average expert sentiment on the projected Biogen Inc target price to derive its highest and lowest estimates based on target price volatility.
Lowest Forecast
300.99
Highest Forecast
367.14
Target Price
330.76
At present, Biogen's Pretax Profit Margin is projected to increase slightly based on the last few years of reporting. The current year's Operating Profit Margin is expected to grow to 0.14, whereas Gross Profit is forecasted to decline to about 3.9 B. At present, Biogen's Total Assets are projected to increase significantly based on the last few years of reporting. The current year's Short and Long Term Debt Total is expected to grow to about 7.7 B, whereas Cash is forecasted to decline to about 723.1 M.
  
It's important to approach Biogen's target price projections with caution. While they can be useful as part of a broader investment strategy, they are inherently speculative and subject to various kinds of risk, including market volatility and unforeseen external factors. Always consider multiple aspects and do your own research when making investment decisions.

Biogen Target Price Consensus

We track the performance of the top 100 financial experts across various large and mid-size financial boutiques. Biogen target price is determined by taking all analyst projections and averaging them out. There is no one specific way to measure analysts' performance other than comparing it to past results via a very sophisticated attribution analysis. Biogen's target price projections below should be used in combination with other traditional price prediction techniques such as stock price forecasting, investor sentiment analysis, technical analysis, earnings estimate, and various momentum models.
   35  Strong Buy
Most Biogen analysts issue ratings four times a year, at intervals of three months. Ratings are usually accompanied by a target price to help potential investors understand Biogen stock's fair price compared to its market value. Analysts arrive at stock ratings after researching the public financial statements of Biogen Inc, talking to its executives and customers, or listening to those companies' conference calls.
Macroaxis Advice   Exposure   Valuation

Biogen Target Price Projection

Biogen's current and average target prices are 230.06 and 330.76, respectively. The current price of Biogen is the price at which Biogen Inc is currently trading. On the other hand, Biogen's target price is what analysts think the stock is worth or could sell for in the future. The more significant the discrepancy between the two prices, the more it stimulates investors to act.

Current Price

Biogen Market Quote on 13th of July 2024

Low Price226.5Odds
High Price237.98Odds

230.06

Target Price

Analyst Consensus On Biogen Target Price

Low Estimate300.99Odds
High Estimate367.14Odds

330.76

Historical Lowest Forecast  300.99 Target Price  330.76 Highest Forecast  367.14
Note that most analysts generally publish their price targets in research reports on specific companies, along with recommendations for the company's stock.Although price targets are often quoted in the financial news media, there could be a delay between the publication of the latest analyst outlook on Biogen Inc and the information provided on this page.

Biogen Analyst Ratings

Biogen's analyst stock recommendations are determined by taking an average estimate of all analysts we track and classifying them as Strong Buy, Buy, Hold, Strong Sell, or Sell. Ratings generally communicate what analysts sense about Biogen stock, and they use a lot of effort and time to analyze it and arrive at a rating. That suggests that analyst recommendations are the outcome of an objective and thorough examination of Biogen's financials, market performance, and future outlook by experienced professionals. Biogen's historical ratings below, therefore, can serve as a valuable tool for investors.

Analyst Consensus Breakdown

Average Consensus Estimates

Analysts determine stock price targets through various methods, including financial modeling, peer comparison, and company analysis. The stock price target is the analyst's best estimate of the future price of a stock and is used by investors to make investment decisions. However, it is important to note that stock price targets are not guaranteed, and the actual price of a stock can differ significantly from the target due to various factors such as market conditions, economic events, and company developments.

Steps to utilize Biogen price targets

Biogen's stock target price is an estimate of its future price, usually made by analysts. Using Biogen's target price to determine if it is a suitable investment can be done through the following steps:
  • Look at Biogen's target prices provided by various analysts and compare them. This can help you gain a more balanced view of the Stock's potential.
  • Look at the analyst's track record to determine if they have a history of accurately predicting stock prices.
  • Look at the Company's financials, including revenue, earnings, and debt, to determine if it is in good financial health.
  • Consider market conditions. For example, take into account the state of the economy, competition, and regulatory environment, to determine if Biogen's stock is likely to perform well.
  • Diversify your portfolio and do not rely solely on stock target prices to make investment decisions. Invest in a mix of stocks, bonds, and other assets to manage risk.
Remember that stock target prices are just estimates and are subject to change. Therefore, using them as one factor in a larger investment strategy is essential rather than relying solely on them to make decisions.

Additional Biogen Value Projection Modules

Most investment researchers agree that the mispricing and readjustment of any Stock value happens often and is sometimes even predictable, but there is no strong theory explaining why it happens. The current price of Biogen is a key component of Biogen valuation and have some predictive power on the future returns of a Biogen.
Sophisticated investors, who have witnessed many market ups and downs, anticipate that the market will even out over time. This tendency of Biogen's price to converge to an average value over time is called mean reversion. However, historically, high market prices usually discourage investors that believe in mean reversion to invest, while low prices are viewed as an opportunity to buy.
Hype
Prediction
LowEstimatedHigh
228.79230.48232.17
Details
Intrinsic
Valuation
LowRealHigh
207.05248.20249.89
Details
Naive
Forecast
LowNextHigh
230.28231.96233.65
Details
Earnings
Estimates (0)
LowProjected EPSHigh
3.433.996.04
Details
Please note, it is not enough to conduct a financial or market analysis of a single entity such as Biogen. Your research has to be compared to or analyzed against Biogen's peers to derive any actionable benefits. When done correctly, Biogen's competitive analysis will give you plenty of quantitative and qualitative data to validate your investment decisions or develop an entirely new strategy toward taking a position in Biogen Inc.

Trending Themes

If you are a self-driven investor, you will appreciate our idea-generating investing themes. Our themes help you align your investments inspirations with your core values and are essential building blocks of your portfolios. A typical investing theme is an unweighted collection of up to 20 funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of equities with common characteristics such as industry and growth potential, volatility, or market segment.
Banking Idea
Banking
Invested over 30 shares
Business Services Idea
Business Services
Invested few shares
Investor Favorites Idea
Investor Favorites
Invested few shares
Automobiles and Trucks Idea
Automobiles and Trucks
Invested over 60 shares
FinTech Idea
FinTech
Invested over 70 shares
Warren Buffett Holdings Idea
Warren Buffett Holdings
Invested over 40 shares
Adviser Favorites Idea
Adviser Favorites
Invested few shares
Macroaxis Index Idea
Macroaxis Index
Invested over 500 shares
Management Idea
Management
Invested over 30 shares

Additional Information and Resources on Investing in Biogen Stock

When determining whether Biogen Inc offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Biogen's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Biogen Inc Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Biogen Inc Stock:
Check out Macroaxis Advice on Biogen to cross-verify analyst projections. Unlike analyst recommendations, Macroaxis provides advice only from the perspective of investor risk tolerance and investment horizon.
You can also try the Equity Forecasting module to use basic forecasting models to generate price predictions and determine price momentum.
The data published in Biogen's official financial statements typically reflect Biogen's business processes, product offerings, services, and other fundamental events. However, there are additional fundamental indicators that are easier to understand and visualize along the underlying realities that are driving Biogen's quantitative information. For example, before you start analyzing numbers published by Biogen accountants, it's essential to understand Biogen's liquidity, profitability, and earnings quality within the context of the Biotechnology space in which it operates.
Please note, the presentation of Biogen's financial position, as portrayed in its financial statements, is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Biogen's management is honest, while the outside auditors are strict and uncompromising. Please utilize our Beneish M Score to check the likelihood of Biogen's management manipulating its earnings.